More importantly, the combination of the MALAT1 inhibitor MALAT1-IN1 with sorafenib significantly enhanced the therapeutic efficacy of sorafenib in the treatment of HCC both in vitro and in vivo [95]. The gene discussed is MALAT1; the disease is hepatocellular carcinoma.